The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 causes high morbidity and
mortality worldwide. SARS-CoV-2 vaccination is currently the most effective means of
reducing morbidity, severe illness and mortality risk. Metabolic associated fatty liver
disease (MAFLD) has a prevalence rate of 29.63% in China, which is the most common
chronic liver disease in China. This study aimed to establish a metabolic associated
fatty liver disease (MAFLD) cohort of sequential booster SARS-CoV-2 vaccination, and to
identify the dynamic changes of immune response induced by sequential booster SARS-CoV-2
vaccination in MAFLD population. To investigate the effects of blood routine, liver
function biochemistry and coagulation function at 28 days, 57 days and 180 days after
inoculation of SARS-CoV-2 vaccination. Safety and adverse events were assessed using an
electronic questionnaire at days 1, 3, 5, and 7 after enrollment. Serum and peripheral
blood PBMC were collected at baseline and 28, 57, and 180 days after vaccination. Blood
routine, liver function biochemistry, coagulation function, antibodies, peripheral blood
cell subtypes and serum, and PBMC proteomics were tested to evaluate the antibody and
immune response induced by SARS-CoV-2 vaccination.